Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 21.92% | 12.36% | 5.44% | 21.58% | 40.58% |
| Gross Profit | -21.92% | -12.36% | -5.44% | -21.58% | -40.58% |
| SG&A Expenses | 23.01% | 14.09% | 4.66% | -5.97% | -3.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.14% | 12.72% | 5.27% | 14.65% | 28.47% |
| Operating Income | -22.14% | -12.72% | -5.27% | -14.65% | -28.47% |
| Income Before Tax | 13.49% | 14.12% | 25.36% | 30.66% | -11.22% |
| Income Tax Expenses | -100.00% | -100.00% | -129.41% | -128.00% | -88.57% |
| Earnings from Continuing Operations | 13.49% | 14.12% | 25.39% | 30.68% | -11.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.49% | 14.12% | 25.39% | 30.68% | -11.20% |
| EBIT | -22.14% | -12.72% | -5.27% | -14.65% | -28.47% |
| EBITDA | -- | -- | -- | 68.60% | 32.61% |
| EPS Basic | 33.70% | 31.22% | 38.50% | -121.98% | -409.72% |
| Normalized Basic EPS | 18.35% | 23.18% | 42.78% | 64.09% | 79.55% |
| EPS Diluted | 33.70% | 31.22% | 38.50% | -121.98% | -409.72% |
| Normalized Diluted EPS | 18.35% | 23.18% | 42.78% | 64.09% | 79.55% |
| Average Basic Shares Outstanding | 31.77% | 29.55% | 36.19% | 59.21% | 122.73% |
| Average Diluted Shares Outstanding | 31.77% | 29.55% | 36.19% | 59.21% | 122.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |